Effect of Adjuvant Chemotherapy on Survival Among Patients with Stage IIA Colorectal Cancer Following Radical Surgery: A Propensity Score-Matching Study Using the SEER Database.

IF 2.2 4区 医学 Q3 ONCOLOGY
Cancer Investigation Pub Date : 2026-01-01 Epub Date: 2025-12-09 DOI:10.1080/07357907.2025.2593470
Qilong Lan, Lanlan Xie, Dongbo Xu, Shuangming Lin, Changyu Li
{"title":"Effect of Adjuvant Chemotherapy on Survival Among Patients with Stage IIA Colorectal Cancer Following Radical Surgery: A Propensity Score-Matching Study Using the SEER Database.","authors":"Qilong Lan, Lanlan Xie, Dongbo Xu, Shuangming Lin, Changyu Li","doi":"10.1080/07357907.2025.2593470","DOIUrl":null,"url":null,"abstract":"<p><p>To explore the effect of adjuvant chemotherapy on the overall survival (OS) and cancer cause-specific survival (CSS) in patients with AJCC stage IIA colorectal cancer. Date of patients with stage IIA colorectal cancer who underwent radical surgery without radical therapy or preoperative chemotherapy were retrieved from the Surveillance, Epidemiology, and End Results database. Propensity score matching (1:1) was performed, yielding a cohort of 14819 patients. The 3-, 5- and 7- year OS rates in the non-chemotherapy group were 80.5%, 50.0% and 16.3%, respectively, compared with 97.2%, 86.0% and 57.3% in the chemotherapy group. Regardless of the risk factors, adjuvant chemotherapy significant improved the OS (<i>p</i> = 0.000), but not for CSS. The Cox proportional-hazards model revealed that age ≥ 65 years, male sex, unmarried status, rectal carcinoma, positive carcinoembryonic antigen, perineural invasion positive, fewer than 12 lymph nodes and multiple cancers were risk factors for both OS and CSS. However, adjuvant chemotherapy was a risk factor only for OS. Regardless of these risk factors or the presence of multiple cancers, adjuvant chemotherapy markedly improved OS in patients with stage IIA colorectal cancer, particularly in those with grade III/IV tumors or fewer than 12 lymph nodes, but has not been proven on CSS.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"39-50"},"PeriodicalIF":2.2000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2025.2593470","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

To explore the effect of adjuvant chemotherapy on the overall survival (OS) and cancer cause-specific survival (CSS) in patients with AJCC stage IIA colorectal cancer. Date of patients with stage IIA colorectal cancer who underwent radical surgery without radical therapy or preoperative chemotherapy were retrieved from the Surveillance, Epidemiology, and End Results database. Propensity score matching (1:1) was performed, yielding a cohort of 14819 patients. The 3-, 5- and 7- year OS rates in the non-chemotherapy group were 80.5%, 50.0% and 16.3%, respectively, compared with 97.2%, 86.0% and 57.3% in the chemotherapy group. Regardless of the risk factors, adjuvant chemotherapy significant improved the OS (p = 0.000), but not for CSS. The Cox proportional-hazards model revealed that age ≥ 65 years, male sex, unmarried status, rectal carcinoma, positive carcinoembryonic antigen, perineural invasion positive, fewer than 12 lymph nodes and multiple cancers were risk factors for both OS and CSS. However, adjuvant chemotherapy was a risk factor only for OS. Regardless of these risk factors or the presence of multiple cancers, adjuvant chemotherapy markedly improved OS in patients with stage IIA colorectal cancer, particularly in those with grade III/IV tumors or fewer than 12 lymph nodes, but has not been proven on CSS.

辅助化疗对IIA期结直肠癌根治术后患者生存的影响:使用SEER数据库的倾向评分匹配研究
探讨辅助化疗对AJCCⅱ期结直肠癌患者总生存期(OS)和癌因特异性生存期(CSS)的影响。从监测、流行病学和最终结果数据库中检索接受根治性手术而未接受根治性治疗或术前化疗的IIA期结直肠癌患者的日期。进行倾向评分匹配(1:1),产生14819例患者。非化疗组3年、5年和7年的OS率分别为80.5%、50.0%和16.3%,化疗组为97.2%、86.0%和57.3%。无论何种危险因素,辅助化疗均显著改善了OS (p = 0.000),但对CSS无显著改善。Cox比例风险模型显示,年龄≥65岁、男性、未婚、直肠癌、癌胚抗原阳性、周围神经浸润阳性、少于12个淋巴结和多发性肿瘤是OS和CSS的危险因素。然而,辅助化疗仅是OS的危险因素。不考虑这些危险因素或存在多种癌症,辅助化疗显著改善了IIA期结直肠癌患者的OS,特别是III/IV级肿瘤或小于12个淋巴结的患者,但尚未证实其对CSS的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Investigation
Cancer Investigation 医学-肿瘤学
CiteScore
3.80
自引率
4.20%
发文量
71
审稿时长
8.5 months
期刊介绍: Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书